Transparency Market

Research
Epigenetics Drugs and Diagnostic
Technologies Market is growing at
a CAGR of 19.4 fro! "#1$ to
"#19. %& Transparenc& Market
Research.
Single User License:
USD 4595
Multi User License:
USD 7595
Corporate User License:
USD 10595
Epigenetics Drugs and Diagnostic Technologies Market is
E'pected to Reach ()D *.+ %illion Glo,all& in "#1-.
Transparenc& Market Research
Transparency Market Research
)tate Tower/
9#/ )tate )treet/ )uite +##.
Al,an&/ 01 1""#+
(nited )tates
www.transparenc&!arketresearch.co!
sales2transparenc&!arketresearch.co!
112 Page Report
Publise! Date
2"#$une#201%
&u' (o)
Re*uest Sa+ple
Press Release
Epigenetics Drugs and
Diagnostic Technologies
Market
Epigenetics Drugs and Diagnostic Technologies Market was valued at USD 1.6 billion in 201 and
is esti!ated to reach a !arket worth USD ".# billion in 201$ at a %&'( o) 1$.*+ )ro! 201 to
201$.
&ro)se te ,ull report at ttp:--))).transparenc'+ar/etresearc.co+-epigenetics#
+ar/et.t+l
The growth o) the epigenetics !arket is driven b, )actors such as increase in aging population-
as there is a strong correlation between cancer and aging. &ccording to ./0- it is esti!ated that
global population over the age o) 60 ,ears would double )ro! 11+ 120002 to 22+ 120"02. 3eople
aged 60 and above are !ore prone to cancer. /ence- countries are advocating earl, detection o)
cancer through screening kits 1Epi 3rocolon- Epi 3ro4ung2 which are driving the epigenetic drugs
and diagnostic technologies !arket.
Epigenetic drugs !ake it possible to reverse the aberrant gene e5pression which leads to various
disease states. The inhibitors- D6& !eth,ltrans)erase 1D6MT2 and /istone Deacet,lase 1/D&%2
are responsible )or regulating the cellular e5pression. 0ut o) the two inhibitors- D6MT accounts
)or a larger share as these inhibitors o7er an i!proved access )or targeting the cancerous cells.
%urrentl,- )our drugs are approved b, 8D& and are co!!erciall, available. Two o) the! are
D6MT inhibitors9 %elgene:s ;ida<a 1a<acitidine2 and Eisai:s Dacogen 1decitabine2 )or the
treat!ent o) M,elod,splastic S,ndro!e 1MDS2- and the other two are /D&% inhibitors9 Merck:s
=olin<a 1vorinostat2 and %elgene:s >stoda5 1ro!idepsin2 both )or treat!ent o) %utaneous T %ell
4,!pho!a 1%T%42.
Epigenetics is a rapidl, developing ?eld not onl, in oncolog, but also in non@oncolog, indications
1&l<hei!er:s and arthritis2. Due to the increase in disease identi?cation- !anu)acturers are taking
initiatives in develop!ent o) varied epigenetic diagnostic techniAues. D6& !eth,lation
techniAue in the diagnostic seg!ent accounts )or the largest share as co!pared to histone
!odi?cation techniAues- as the research on D6& !eth,lation has been carried out since
decades- and is thus !ostl, pre)erred. 8urther!ore- with the corresponding advance!ents in
research and technolog,- histone code h,pothesis techniAue ca!e into e5istence onl, in late
Transparenc& Market Research
2
R0P1R2 D0SCR3P231(
Epigenetics Drugs and
Diagnostic Technologies
Market
1$B0s. /ence- with the surge in interest- there is also an increase in invest!ent )or the research
and develop!ent o) histone !odi?cations.
6orth &!erica accounts )or the largest share o) the epigenetics !arket. >t is e5pected that 6orth
&!erica will do!inate around hal) o) the global epigenetics !arket due to increasing incidence
o) cancer and other non@oncolog, indications. 0ncolog, and other non@oncolog, indications
1&l<hei!er:s and arthritis2 are associated with epigeneticsC thus the increasing incidence o)
cancer supports the growth o) the epigenetics !arket. &sia accounts )or nearl, hal) o) the new
cancer cases worldwide. The rising incidence o) cancer cases in the &sian region would boost the
de!and )or epigenetic drugs and diagnostic technologies in this !arket. &ustralia- %hina- Dapan
and South Eorea are the largest !arkets )or these therapies. Dapan do!inates the epigenetics
!arket in &sia@3aci?c due to a signi?cant presence o) co!panies in the therapeutics seg!ent
such as Eisai 3har!aceuticals and 0ncol,s Fiophar!a. These co!panies are taking initiatives )or
the develop!ent and co!!erciali<ation o) epigenetic drugs. ;arious research institutes and
invest!ents )ro! these co!panies would drive the epigenetics !arket.
So!e o) the ke, pla,ers in this !arket include %elgene %orporation- Merck- Eisai
3har!aceuticals- E5act Sciences- Epigeno!ics and others. Manu)acturers are entering into
strategic alliances with nu!erous research institutions and other pla,ers )or the develop!ent
and co!!erciali<ation o) new and innovative drugs- which !ight see new pla,ers in the !arket
looking to carve out a share o) the !arket )or the!selves.
The epigenetics drugs and diagnostic technologies !arket is seg!ented as )ollows9
Epigenetics Drugs Market- b, Mechanis! o) &ction
D6MT >nhibitors
Epigenetics Diagnostic Technologies Market- b, T,pes
D6& Meth,lation
%hro!atin >!!unoprecipitation 1%h>32 Technolog,
Epigenetics Technologies Market- b, 'eograph,
6orth &!erica
Europe
Transparenc& Market Research

Epigenetics Drugs and

Diagnostic Technologies
Market
&sia@3aci?c
(o.
4or Sa+ple Report 5isit 1n:
ttp:--))).transparenc'+ar/etresearc.co+-sa+ple-sa+ple.pp67ag8S9rep:i!8422
Capter 1 Pre,ace
1.1 Report Description
1.2 Mar/et Seg+entation
1.% Researc Meto!olog'
Capter 2 0;ecuti<e Su++ar'
2.1 Mar/et Snapsot: =lobal 0pigenetics Mar/et >2011 9 201?@
2.2 =lobal 0pigenetics Mar/etA b' Seg+entsA 2011 >USD Million@
Capter % Mar/et 1<er<ie)
%.1 3ntro!uction
%.2 Mar/et Dri<ers
Transparenc& Market Research
*
2B&L0 14 C1(20(2
Epigenetics Drugs and
Diagnostic Technologies
Market
%.2.1 3ncrease in De+an! ,or te 2reat+ent o, 1ncolog' an! (on#1ncolog' Con!itions
%.2.2 Cuge B+ounts o, 3n<est+ent
%.2.% B!<ances in Screening 2ools
%.2.4 3+pact Bnal'sis o, Mar/et Dri<ers
%.% Mar/et Restraints
%.%.1 =enericiDation o, MaEor Drugs
%.%.2 3+pact Bnal'sis o, Mar/et Restraints
%.4 Mar/et 1pportunities
%.5 PorterFs 4i<e 4orces Bnal'sis
%.5.1 &argaining Po)er o, &u'ers
%.5.2 &argaining Po)er o, Suppliers
%.5.% 2reat o, (e) 0ntrants
%.5.4 2reat o, Substitutes
%.5.5 Co+petiti<e Ri<alr'
%." Mar/et Bttracti<eness Bnal'sis
Capter 4 0pigenetics Drugs Mar/etA &' Mecanis+ 1, Bction
4.1 1<er<ie)
4.1.1 =lobal 0pigenetic Drugs Mar/etA &' Mecanis+ 1, BctionA 2010 G 201? >USD Million@
4.1.2 Cistone Deacet'lase >CDBC@ 3nibitors
Transparenc& Market Research
"
Epigenetics Drugs and
Diagnostic Technologies
Market
4.1.% =lobal CDBC 3nibitors Mar/etA &' DrugsA 2010 G 201? >USD Million@
4.1.%.1 5orinostat
4.1.%.2 =lobal 5orinostat Mar/etA &' 2'pes 2010 G 201? >USD Million@
4.1.%.% Ro+i!epsin
4.1.%.4 =lobal Ro+i!epsin Mar/etA &' 2'pes 2010 G 201? >USD Million@
4.1.4 D(B Met'ltrans,erase >D(M2@ 3nibitors
4.1.5 =lobal D(M2 3nibitors Mar/etA &' DrugsA 2010G201? >USD Million@
4.1.5.1 Decitabine
4.1.5.2 =lobal Decitabine Mar/etA &' 2'pes 2010 G 201? >USD Million@
4.1.5.% BDaciti!ine
4.1.5.4 =lobal BDaciti!ine Mar/etA &' 2'pes 2010 G 201? >USD Million@
4.1." Pipeline Drugs
4.1.".1 Mocetinostat
4.1.".2 Bbe;inostat
4.1.".% Res+inostat
4.1.".4 Rocilinostat
4.1.".5 CCR %99"
4.1."." 05P 0%%4
4.1.".7 Panobinostat
4.1.".? &elinostat
Transparenc& Market Research
6
Epigenetics Drugs and
Diagnostic Technologies
Market
4.1.".9 0ntinostat
4.1.".10 5alproic Bci!
4.1.".11 Cistone Met'ltrans,erase >CM2@ 3nibitors
Capter 5 0pigenetics Diagnostic 2ecnolog' Mar/etA &' 2'pes
5.1 1<er<ie)
5.1.1 =lobal 0pigenetic Diagnostic 2ecnologies Mar/etA &' 2'pesA 2010 G 201? >USD
Million@
5.2 D(B Met'lation
5.2.1.1 =lobal D(B Met'lation 2ecnolog' Mar/etA &' 2'pes 2010 G 201? >USD
Million@
5.2.2 Cro+atin 3++unoprecipitation >Cip@
5.2.2.1 =lobal Cro+atin 3++unoprecipitation >Cip@ 2ecnolog' Mar/etA &' 2'pes
2010 G 201? >USD Million@
Capter " =lobal 0pigenetics 2ecnologies Mar/etA &' =eograp'
".1 1<er<ie)
".1.1 =lobal 0pigenetics 2ecnologies Mar/etA &' =eograp'A 2010G201? >USD Million@
".2 Co+parati<e Bnal'sis: 0pigenetic 2ecnologies Mar/etA &' =eograp'A 2011 9 201? >5alue
H@
".% (ort B+erica
Transparenc& Market Research
#
Epigenetics Drugs and
Diagnostic Technologies
Market
".%.1 (ort B+erica 0pigenetics 2ecnologies Mar/etA &' =eograp'A 2010 G 201? >USD
Million@
".4 0urope
".4.1 0urope 0pigenetics 2ecnologies Mar/etA &' =eograp'A 2010 G 201? >USD Million@
".5 Bsia#PaciIc
".5.1 Bsia#PaciIc 0pigenetics 2ecnologies Mar/etA &' =eograp'A 2010 G 201? >USD
Million@
"." Rest o, te Jorl!
".".1 Ro) 0pigenetics 2ecnologies Mar/etA &' =eograp'A 2010 G 201? >USD Million@
Capter 7 Co+petiti<e Lan!scape
7.1 Mar/et Sare Bnal'sisA &' Ke' Pla'ers >H@
Capter ? Reco++en!ations
?.1 Mar/et Strateg' ,or Success
?.2 &arriers to be Consi!ere!
Capter 9 Co+pan' ProIles
9.1 4SC B=
9.1.1 Co+pan' 1<er<ie)
9.1.2 4inancial 1<er<ie)
9.1.% Pro!uct 1<er<ie)
9.1.4 &usiness Strateg'
Transparenc& Market Research
B
Epigenetics Drugs and
Diagnostic Technologies
Market
9.1.5 Recent De<elop+ents
9.2 Bcet'lon Par+aceuticalsA 3nc.
9.2.1 Co+pan' 1<er<ie)
9.2.2 4inancial 1<er<ie)
9.2.% Pro!uct 1<er<ie)
9.2.4 &usiness Strateg'
9.2.5 Recent De<elop+ents
9.% Bste; Par+aceuticals 3nc.
9.%.1 Co+pan' 1<er<ie)
9.%.2 4inancial 1<er<ie)
9.%.% Pro!uct Port,olio
9.%.4 &usiness Strateg'
9.%.5 Recent De<elop+ents
9.4 Cellcentric Lt!.
9.4.1 Co+pan' 1<er<ie)
9.4.2 4inancial 1<er<ie)
9.4.% Pro!uct Port,olio
9.4.4 &usiness Strateg'
9.4.5 Recent De<elop+ents
9.5 Celleron 2erapeutics Lt!.
Transparenc& Market Research
$
Epigenetics Drugs and
Diagnostic Technologies
Market
9.5.1 Co+pan' 1<er<ie)
9.5.2 4inancial 1<er<ie)
9.5.% Pro!uct Port,olio
9.5.4 &usiness Strateg'
9." Celgene Corporation
9.".1 &usiness 1<er<ie)
9.".2 4inancial 1<er<ie)
9.".% &usiness Strateg'
9.".4 Recent De<elop+ents
9.7 Cro+a 2erapeutics Lt!.
9.7.1 Co+pan' 1<er<ie)
9.7.2 4inancial 1<er<ie)
9.7.% Pro!uct 1<er<ie)
9.7.4 &usiness Strateg'
9.7.5 Recent De<elop+ents
9.? 0pigente/ =roup 3nc.
9.?.1 &usiness 1<er<ie)
9.?.2 4inancial 1<er<ie)
9.?.% &usiness Strateg'
9.?.4 Recent De<elop+ents
Transparenc& Market Research
10
Epigenetics Drugs and
Diagnostic Technologies
Market
9.9 0isai Co. Lt!.
9.9.1 Co+pan' 1<er<ie)
9.9.2 4inancial 1<er<ie)
9.9.% Pro!uct Port,olio
9.9.4 &usiness Strateg'
9.9.5 Recent De<elop+ents
9.10 0n<i<o Par+aceuticals 3nc.
9.10.1 Co+pan' 1<er<ie)
9.10.2 4inancial 1<er<ie)
9.10.% Pro!uct Port,olio
9.10.4 &usiness Strateg'
9.11 0piD'+eA 3nc.
9.11.1 Co+pan' 1<er<ie)
9.11.2 4inancial 1<er<ie)
9.11.% Pro!uct Port,olio
9.11.4 &usiness Strateg'
9.11.5 Recent De<elop+ents
9.12 3llu+ina 3nc.
9.12.1 Co+pan' 1<er<ie)
9.12.2 4inancial 1<er<ie)
Transparenc& Market Research
11
Epigenetics Drugs and
Diagnostic Technologies
Market
9.12.% Pro!uct Port,olio
9.12.4 &usiness Strategies
9.12.5 Recent De<elop+ents
9.1% M!;ealt
9.1%.1 Co+pan' 1<er<ie)
9.1%.2 4inancial 1<er<ie)
9.1%.% Pro!uct Port,olio
9.1%.4 &usiness Strateg'
9.1%.5 Recent De<elop+ents
9.14 Merc/ 9 Co+pan' 3nc.
9.14.1 Co+pan' 1<er<ie)
9.14.2 4inancial 1<er<ie)
9.14.% Pro!uct Port,olio
9.14.4 &usiness Strateg'
9.15 (o<artis 3nternational B=
9.15.1 Co+pan' 1<er<ie)
9.15.2 4inancial 1<er<ie)
9.15.% Pro!uct Port,olio
9.15.4 &usiness Strateg'
9.15.5 Mergers Bn! Bc*uisitions
Transparenc& Market Research
12
Epigenetics Drugs and
Diagnostic Technologies
Market
9.1" 1ncol's &iopar+a 3nc.
9.1".1 Co+pan' 1<er<ie)
9.1".2 4inancial 1<er<ie)
9.1".% Pro!uct Port,olio
9.1".4 &usiness Strateg'
9.17 Par+ac'clicsA 3nc.
9.17.1 Co+pan' 1<er<ie)
9.17.2 4inancial 1<er<ie)
9.17.% Pro!uct Port,olio
9.17.4 &usiness Strateg'
9.17.5 Recent De<elop+ents
9.1? Pro+ega Corporation
9.1?.1 Co+pan' 1<er<ie)
9.1?.2 4inancial 1<er<ie)
9.1?.% Pro!uct Port,olio
9.1?.4 &usiness Strateg'
9.1?.5 Recent De<elop+ents
9.19 Repligen Corporation
9.19.1 Co+pan' 1<er<ie)
9.19.2 4inancial 1<er<ie)
Transparenc& Market Research
1
Epigenetics Drugs and
Diagnostic Technologies
Market
9.19.% Pro!uct Port,olio
9.19.4 &usiness Strateg'
9.19.5 Recent De<elop+ents
9.20 Spectru+ Par+aceuticals
9.20.1 Co+pan' 1<er<ie)
9.20.2 4inancial 1<er<ie)
9.20.% Pro!uct Port,olio
9.20.4 &usiness Strateg'
9.20.5 Recent De<elop+ents
9.21 S'n!a; Par+aceuticalsA 3nc.
9.21.1 Co+pan' 1<er<ie)
9.21.2 4inancial 1<er<ie)
9.21.% Pro!uct Port,olio
9.21.4 &usiness Strateg'
9.21.5 Recent De<elop+ents
9.22 2opotarget B-S
9.22.1 Co+pan' 1<er<ie)
9.22.2 4inancial 1<er<ie)
9.22.% Pro!uct Port,olio
9.22.4 &usiness Strateg'
Transparenc& Market Research
1*
Epigenetics Drugs and
Diagnostic Technologies
Market
9.22.5 Recent De<elop+ents
9.2% 5alir; Plc
9.2%.1 Co+pan' ProIle
9.2%.2 4inancial 1<er<ie)
9.2%.% Pro!uct Port,olio Bn! 2ecnolog'
9.2%.4 &usiness Strateg'
9.2%.5 Recent De<elop+ents
Transparenc, Market (esearch is a !arket intelligence co!pan, providing global business in)or!ation
reports and services. 0ur e5clusive blend o) Auantitative )orecasting and trends anal,sis provides )orward@
looking insight )or thousands o) decision !akers.
.e are privileged with highl, e5perienced tea! o) &nal,sts- (esearchers and %onsultants- who use
proprietar, data sources and various tools and techniAues to gather- and anal,<e in)or!ation. 0ur
business o7erings represent the latest and the !ost reliable in)or!ation indispensable )or businesses to
sustain a co!petitive edge.
Contact:
Transparenc, Market (esearch
$0 State Street-
Suite #00-
&lban,
6G @ 1220#
United States
Tel9 H1@"1B@61B@100
US& @ %anada Toll 8ree B66@""2@*"
E!ail9 salesItransparenc,!arketresearch.co!
.ebsite9 http9JJwww.transparenc,!arketresearch.co!J
Transparenc& Market Research
1"
Bbout Us